Table 1.
Demographic characteristics of the University of Chicago ALL cohort (n = 221)
| N (%) | |
|---|---|
| Age, median (range), y | 43 (18-88) |
| Female sex, n (%) | 105 (48) |
| BMI, n (%) | |
| <30 | 150 (68) |
| 30-40 | 54 (24) |
| >40 | 17 (8) |
| Race/ethnicity, n (%) | |
| NHW | 131 (59) |
| Hispanic | 48 (22) |
| NHB | 33 (15) |
| Asian | 7 (3) |
| >1 race | 2 (1) |
| Median income, n (%) | |
| High | 129 (59) |
| Middle | 73 (33) |
| Low | 17 (8) |
| Immunophenotype, n (%) | |
| B-ALL | 185 (84) |
| Pre–T-ALL | 25 (11) |
| ETP-ALL | 11 (5) |
| ALL subtype, n (%) | |
| B-ALL | |
| Ph+ | 50 (23) |
| Ph-like | 26 (12) |
| Low hypodiploid | 17 (8) |
| KMT2A-rearranged | 13 (6) |
| High hyperdiploid | 8 (4) |
| T-ALL | |
| HOXA-dysregulated | 10 (5) |
| TAL1-rearranged | 5 (3) |
| Firstline therapy | |
| CALGB 10403 based | 104 (47) |
| HyperCVAD based | 41 (19) |
| CALGB 10701 | 25 (11) |
| Lower-intensity chemotherapy | 12 (5) |
| TKI + antibody | 11 (5) |
| A41703 | 7 (3) |
| Mini-hyperCVD + venetoclax | 7 (3) |
| Inotuzumab | 5 (2) |
| TKI | 4 (2) |
| Asciminib + dasatinib | 3 (1) |
| Blinatumomab | 2 (1) |
| Allogeneic HCT, n (%) | 49 (22) |
CVAD, cyclophosphamide, vincristine, adriamycin, dexamethasone; ETP, early T precursor; HCT, hematopoietic cell transplant; Ph, Philadelphia chromosome; T-ALL, T-cell ALL; TKI, tyrosine kinase inhibitor.